>MNTA – My impression is Fragmin was a bit more challenging [than Lovenox] and they didn't succeed.<
If that’s true, it presumably means that they didn’t try hard enough on Fragmin because they saw that Fragmin’s puny sales made the goal not worth the effort.
Fragmin and Lovenox are derived from the same API. They are produced using similar kinds of intermediate-stage reactions. The constituent heparin chains in the final products are also similar as measured by the proportion of chains with a given molecular weight. In short, it’s hard to see why one of these drugs would be very much harder to reverse engineer than the other.
Although the Fragmin program is defunct, I consider it a matter of some consequence that MNTA’s technology per se was not lacking.
Market Data 
Markets 
AI
